APE1-IN-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

APE1-IN-1 是一种有效且具有血脑屏障透过性的无嘌呤/嘧啶内切酶 1 (APE1) 抑制剂，IC50 为 2 μM。APE1-IN-1 可增强烷基化剂甲基甲烷磺酸盐 (Methylmethane sulfonate) 和 Temozolomide (HY-17364) 对癌细胞的细胞毒性。

APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells.

APE1-IN-1 (compound 3) exhibits an IC50 of 2 μM in the qHTS assay and an IC50 of 12 μM in a radiotracer incision assay (RIA).APE1-IN-1 (0, 1, 3, 10, 30, or 100 μM; 15 min) inhibits HeLa whole cell extract AP site incision in a dose-dependent manner.APE1-IN-1 (5-30 μM; 24 h) exhibits cytotoxic activity against HeLa cells, and potentiates the activity of methyl methansulfonate and Temozolomide (HY-17364).Cell Cytotoxicity Assay Cell Line:HeLa cells Concentration:5-30 μM Incubation Time:24 h Result:Exhibited cytotoxic activity against HeLa cells with a 50% reduction in cell viability occurring at ~15 μM.Greatly potentiated the activity of methyl methansulfonate (0.4 mM) and Temozolomide (HY-17364) (1 mM) with optimal synergy occurring at ~5 μM and ~10 μM, respectively.

APE1-IN-1 (30 mpk; IP; single dosage) exhibits favorable pharmacokinetic property.Pharmacokinetic Parameters of APE1-IN-1 (compound 3) (IP; 30 mpk) in CD1 mice.Animal Model:CD1 male mice (n = 3)Dosage:30 mpk Administration:IP; single dosage Result:Showed lipophilic (CLogP = 2.8), crossed the BBB quite readily, giving rise to a B/P ratio of 21.

——

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNA/RNA Synthesis

——

——

524708-03-0

371.52

C19H21N3OS2

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 22 mg/mL (59.22 mM; 超声助溶 (<80°C)

CC(C)N1CCc2c(C1)sc(NC(C)=O)c2-c1nc2ccccc2s1

——

(-20℃)

With Ice Pack

≥ 2 years